4Q FY26 Quarterly Activity Report and Appendix 4C

• Revenue and profit declined on pcp, reflecting the lingering impact of the challenging pharma budget cycle in the previous period.
• Achieved cashflow break-even in Q4 FY26, as previously guided.
• Net cash at period end of $9.5 million, in line with expectations.
• Strong initial momentum with customers as they enter their next pharma budget cycle.

Adheris Health Limited (ASX: AHE) reported a 44.6% decline in operating revenue for Q4 FY26 to $5.6 million, compared to $10.1 million in the previous year, due to lower customer renewal rates and lower bookings in the first half of FY26. Gross profit decreased, and gross margin fell by 7.1 percentage points to 35.5%. The company achieved cashflow break-even in Q4 FY26, with net operating cash inflow of $0.2 million, and net cash at period end of $9.5 million. The company is focused on advancing its key priorities, including operational scalability, digital access to pharmacy patients, and growth in non-vaccine revenue.